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Several intracellular pathways involved in cell proliferation in adult hippocampus, including 
the endocannabinoid (EC) system, are modulated by antidepressants. To extend our 
knowledge on the regulation of neuroplasticity by antidepressants and the implication of 
EC in these responses, we have evaluated the effects of chronic in vivo exposure to the 
SSRI drug fluoxetine (F) alone or in combination with Δ-9- tetrahydrocannabinol (T) on the 
expression of several neuroplasticity-related systems (β-catenin, AKT, pCREB and BDNF), 
in an animal model of depression. We measured protein levels by western blot in male 
Sprague Dawley bulbectomized rats, treated for 21 days with vehicle (saline), T (10 
mg/kg/day, i.p.), F (10 mg/kg/day, p.o.) and T plus F. Olfactory bulbectomy resulted in a 
significant motor hyperactivity (open field test), reversed by chronic F. Bulbectomized 
animals exhibited a clear decrease (p< 0.05) in the levels of expression of b-catenin, AKT, 
BDNF and pCREB. Both F and T treatments produced an increase of hippocampal  
β -catenin (F= 159±17%, T= 142±70%, p<0.05), AKT, pCREB and BDNF (F= 318±97% T= 
329±90%, p<0.05) levels in bulbectomized rats, with respect to the untreated group. A 
significantly higher effect (P<0.01) was observed following T+F association. Our results 
suggest the existence, in depressive disorders, of a reduced activity of proliferative 
pathways in the hippocampus, that could be reversed by both F and T treatments, 
indicating the possible implication of the EC system in the therapeutic antidepressant 
responses. 
